Last reviewed · How we verify
SOR-C13
At a glance
| Generic name | SOR-C13 |
|---|---|
| Modality | Recombinant protein |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors (PHASE1)
- Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOR-C13 CI brief — competitive landscape report
- SOR-C13 updates RSS · CI watch RSS